Cullinan Therapeutics, Inc.
$15.21
-0.85%Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -4.1).
Valuation inputs: P/E -4.1, earnings yield N/A, momentum -0.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -53.8%, ROIC -58.7%).
Profitability stack: net margin 0.0%, ROE -53.8%, ROIC -58.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +8.8%, momentum -0.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Cullinan Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Cullinan Therapeutics, Inc. Fair Value Envelope
Cullinan Therapeutics, Inc. Profit Bridge
Profitability Analysis
Cullinan Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cullinan Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Cullinan Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that CGEM stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 31.00, with estimates ranging from a low of 28.00 to a high of 37.00.
The consensus 1-year price target stands at 31.00, with estimates ranging from a low of 28.00 to a high of 37.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Cullinan Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $13.32M and sold $1.13M worth of CGEM shares, resulting in $12.19M of net buying activity.
3 Months
0
0.00
7.8K
113.88K
-114K
-$114K
3-6 Months
0
0.00
75.4K
971.90K
-972K
-$972K
6-9 Months
1.9M
13.32M
4.0K
49.20K
+13.3M
+$13.27M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Lynx1 Capital Management Lp
10 Percent Owner
$13.32M
Top Sellers
Michaelson Jennifer
Officer: Chief Scientific Officer
$575K
Ahmed Nadim
Director, Officer: President And Ceo
$295K
Jones Jeffrey Alan
Officer: Chief Medical Officer
$179K
Sumer Jacquelyn L
Officer: Chief Legal Officer
$86K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $12.19M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
CGEM has not reported any dividend yield values in the available annual periods.
cgem Dividend History
Learning Layer
Related Guides
Build conviction on CGEM by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.